Defining The Role Of Microphthalmia-associated Transcription Factor (MITF) In Melanoma Heterogeneity By Real-time Cell Cycle Imaging
Funder
National Health and Medical Research Council
Funding Amount
$613,705.00
Summary
Metastatic melanoma is highly therapy-resistant. Modern targeted therapy is promising but suffers from rapid onset of drug resistance. Tumours consist of zones of fast growing cells next to zones of dormant cells. This tumour heterogeneity is one of the reasons for cancer drug resistance, as cells in different growth states respond differently to drugs. By understanding the causes of tumour heterogeneity we will set the basis for innovative clinical approaches against this devastating disease.
The Western Australia Malignant Pleural Effusions Management Study- What Factors Can Guide Management And Do Indwelling Pleural Catheters Represent The Best Treatment Option?
Funder
National Health and Medical Research Council
Funding Amount
$74,395.00
Summary
This randomised clinical trial will determine whether indwelling tunnelled pleural catheters are the best treatment strategy for patients with malignant pleural effusions. It will also look for ways in which the speed of fluid recurrence can be predicted. It will save public money by finding the most cost effective treatment strategies.
Gastrokine 2: A Novel Stomach-specific Tumour Suppressor Gene
Funder
National Health and Medical Research Council
Funding Amount
$342,735.00
Summary
We will evaluate how a natural protein called gastrokine 2 acts to prevent cancer from developing in the stomach. We will show how gastrokine 2 interacts with another stomach protein TFF1, to block the effects of the inflammatory and cancer causing bacterium Helicobacter pylori, and the way that this bacterium circumvents this by turning off the production of gastrokine 2. Finally a drug which inhibits stomach tumour growth by turning on gastrokine 2 will be tested.
Overweight individuals have an increased risk for developing liver cancer. This may be due to the reduced production of the fat-derived hormone adiponectin. Reduced levels of adiponectin are associated with increased inflammation and liver disease. Using mice not expressing adiponectin we will test its importance in liver cancer growth. The proposed research will provide a better understanding of the factors that promote liver cancer formation.
Immunotherapy has recently shown promise in bone cancer. We have found that while immune modulators Il-6 and Ifn?? contribute to tumour suppression Il-23 promotes the growth of radiation-induced bone cancer. We have generated mouse models of bone cancer to investigate tumour growth and immune surveillance in immune competent mice with an overall aim of identifying therapeutic targets in this disease.